Oppenheimer initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $30 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences price target lowered to $31 from $32 at JMP Securities
- Sagimet Biosciences participates ik,on No
- Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da
- Sagimet Biosciences Advances MASH Treatment with Denifanstat
- Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year